Blue Ocean Capital Group (BOCG) today announced that, as part of its strategy to further deepen its footprint and sharpen its focus in the life sciences sector, its Shenzhen headquarters and affiliated incubation platform Youjoy Incubator will officially relocate Guangming Technology Finance Towerin in Guangming Science City, effective May 1, 2026.This move represents a critical shift of BOCG’s strategic move toward the source of innovation. By embedding itself into one of the world’s leading hubs for life sicence R&D, BOCG aims to strengthen its early-stage enabling capabilities and value-creation partnerships at the forefront of life sciences.

HONG KONG, January 9, 2026 – Ribo LifeScience Co., Ltd. (“Ribo LifeScience” or the “Company,” Stock Code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics and a multi-round investments portfolio company of Blue Ocean Capital Group (“BOCG”), has officially listed on the Main Board of the Hong Kong Stock Exchange. The Company successfully raised approximately HK$1.83 billion (after exercising the offer size adjustment option), marking the second-largest IPO in the 18A biotech sector since 2022 and the first IPO for Blue Ocean Capital in 2026.‍

SHENZHEN, December 2025 – During the Fifth Frontiers of Brain Science and Industry Conference and the 2025 Shenzhen Brain-Computer Interface Expo, Blue Ocean Capital officially announced the establishment of its RMB 160 million (US$23 million) Brain Science Seed Fund. This specialized fund is designed to accelerate the transformation of breakthrough research into market-ready solutions, focusing on the most promising frontiers of life science technologies.